Multiple Sclerosis

Join Clinical Trials for Multiple Sclerosis

Join Clinical Trials for Multiple Sclerosis

General purpose: 
Research related to multiple sclerosis may investigate new drugs in an effort to find more effective treatments for the disease, whereas other studies may investigate how multiple sclerosis develops.

That research can lead to additional research into ways of preventing the development of multiple sclerosis altogether. In addition, research may also focus on the role of the immune system in the development of multiple sclerosis, as well as the impact that genetics has in increasing the risk of multiple sclerosis.

Multiple Sclerosis Clinical Trials Continued … (Click to Open)

Join Clinical Trials for Multiple Sclerosis

Multiple Sclerosis Clinical Trials

What do clinical trials for Multiple Sclerosis involve?

Clinical trials will vary widely in the information they collect, as well as the tests and procedures they use. All of these factors will depend on individual study designs, which will differ greatly between trials. However, below is a list of common procedures and data that are frequently collected during a trial for multiple sclerosis:

  • Blood tests to monitor safety and effectiveness of new drug treatments for multiple sclerosis.
  • Imaging studies, in particular MRI, to monitor the effects of new drugs therapies and other treatments.
  • Blood tests to evaluate specific genetic characteristics or antibodies.
  • Neurological exams
  • Eye exams

Examples of Multiple Sclerosis- related research topics:

  • Studies comparing a conventional treatment for multiple sclerosis with a newly developed drug to determine which is most effective.
  • Studies that use MRI to observe how multiple sclerosis lesions change in size and number within the brain and spinal cord in relation to specific treatments.
  • Studies of blood and tissue samples from large numbers of multiple sclerosis patients in order to observe any common genetic mutations.
  • The effects of pregnancy on women with multiple sclerosis.

Suggested search terms for Multiple Sclerosis:

“Multiple Sclerosis”  “multiple sclerosis treatment,” “multiple sclerosis progression,” “multiple sclerosis diet,” “multiple sclerosis fatigue,” and “multiple sclerosis vitamin D.”



Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Biological: Autologous Hematopoietic Stem Cell;   Drug: BEAM Regimen
Sponsor:   Makati Medical Center
Recruiting - verified May 2017


A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil


Condition:   Multiple Sclerosis
Interventions:   Diagnostic Test: anti-aquaporin-4 antibody;   Diagnostic Test: anti-myelin oligodendrocyte glycoprotein
Sponsors:   Pontificia Universidade Católica do Rio Grande do Sul;   TEVA
Recruiting - verified March 2017


Pilot Diet Study for Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Behavioral: Dietary Intervention;   Behavioral: Non-dietary Intervention Arm
Sponsor:   Icahn School of Medicine at Mount Sinai
Recruiting - verified December 2016


Swiss Multiple Sclerosis Registry


Condition:   Multiple Sclerosis
Intervention:  
Sponsors:   Swiss Multiple Sclerosis Registry;   University of Zurich, Epidemiology, Biostatistics and Prevention Institute;   Schweizerische Multiple Sklerose Gesellschaft
Recruiting - verified November 2016


Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Biological: Ublituximab;   Drug: Placebo
Sponsor:   TG Therapeutics, Inc.
Recruiting - verified January 2017


Pathological Basis of MRI Signal Changes in Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:  
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified December 6, 2016


[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:   Drug: ABT-555
Sponsor:   AbbVie
Terminated - verified February 2017


Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Drug: ponesimod;   Drug: teriflunomide
Sponsor:   Actelion
Active, not recruiting - verified April 2017


Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension


Condition:   Multiple Sclerosis
Intervention:   Other: Observational Cognitive assessments
Sponsors:   Clinique Neuro-Outaouais;   CogState Ltd.
Active, not recruiting - verified July 2016


Trekking Poles to Aid Multiple Sclerosis Gait Impairment


Condition:   Multiple Sclerosis
Interventions:   Other: No device;   Device: Single-point cane (SPC);   Device: Four-point cane (FPC);   Device: Trekking pole (TP).
Sponsor:   Rowan University
Recruiting - verified July 2016


Effect of MD1003 in Spinal Progressive Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Drug: MD1003 100mg capsule;   Drug: Placebo
Sponsor:   MedDay Pharmaceuticals SA
Active, not recruiting - verified March 2017


Physical Telerehabilitation in Veterans With Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:   Device: Multiple Sclerosis Home Automated Telemanagement (MS HAT) system
Sponsors:   University of Maryland;   Baltimore VA Medical Center
Completed - verified May 2017


Upper Limbs Intervention in Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Other: Upper limbs intervention;   Other: Usual treatment
Sponsor:   Universidad de Granada
Completed - verified October 2016


A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)


Condition:   Multiple Sclerosis
Interventions:   Biological: PF-06342674 0.25 mg/kg;   Biological: Placebo;   Biological: PF-06342674 1.5 mg/kg;   Biological: PF-06342674 6.0 mg/kg
Sponsor:   Pfizer
Terminated - verified November 2016


Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Drug: Interferon beta-1a i.m. injections;   Drug: Fingolimod oral capsules;   Drug: Placebo oral capsule;   Drug: Placebo i.m. injection
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified November 2016


Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:   Drug: Fampridine
Sponsor:   Biogen
Completed - verified February 2017


The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:   Drug: Tysabri ® (Natalizumab)
Sponsor:   University of South Florida
Completed - verified February 2017


Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)


Condition:   Multiple Sclerosis
Interventions:   Other: Progressive exercise;   Device: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV;   Other: Modified paleolithic diet;   Dietary Supplement: Omega 3 fatty acids;   Dietary Supplement: Full Spectrum vitamin;   Dietary Supplement: Essential - hydroxytyrosol;   Dietary Supplement: Maltodextrin fiber supplement;   Dietary Supplement: Mineral boost (magnesium);   Dietary Supplement: Niacinamide;   Dietary Supplement: Methyl B12;   Dietary Supplement: Taurine;   Dietary Supplement: creatine;   Dietary Supplement: thiamine;   Dietary Supplement: riboflavin;   Dietary Supplement: N acetylcysteine;   Dietary Supplement: alpha lipoic acid;   Dietary Supplement: L acetyl carnitine;   Dietary Supplement: methyl folate;   Dietary Supplement: coenzyme Q;   Behavioral: meditation;   Behavioral: self massage;   Behavioral: learning;   Dietary Supplement: Coconut oil
Sponsors:   University of Iowa;   Direct MS Canada;   DJO Incorporated;   Pinnaclife Inc.;   TZ Press, LLC
Completed - verified November 2016


Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:   Drug: Teriflunomide (HMR1726)
Sponsor:   Sanofi
Completed - verified December 2016


Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients


Condition:   Multiple Sclerosis
Interventions:   Drug: Ofatumumab 100;   Drug: Ofatumumab 300;   Drug: Ofatumumab 700;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Biological: BG00002 (natalizumab);   Biological: keyhole limpet hemocyanin (KLH);   Biological: tetanus diphtheria toxoid vaccine (Td)
Sponsor:   Biogen
Completed - verified December 2016


Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:   Biological: hematopoetic stem cell infusion
Sponsor:   University of Louisville
Active, not recruiting - verified May 2017


Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks


Condition:   Multiple Sclerosis
Interventions:   Drug: megadose oral methylprednisolone;   Drug: IV methylprednisolone
Sponsors:   Fred Lublin;   National Multiple Sclerosis Society;   Pfizer
Terminated - verified April 2017


Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study


Condition:   Multiple Sclerosis
Interventions:   Procedure: Hematopoietic Stem Cell Therapy;   Drug: Standard treatment with a conventional drug
Sponsors:   Northwestern University;   Uppsala University;   Sheffield Teaching Hospitals NHS Foundation Trust;   University of Sao Paulo
Active, not recruiting - verified May 2017


Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)


Condition:   Multiple Sclerosis
Intervention:  
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 16, 2017

Refine Your Search Advanced Search